[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588121":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":44,"collaborators":11,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":11,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":11,"overallStatus":65,"whyStopped":11,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"British Columbia Cancer Agency","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DOTATATE-PET scan","EXPERIMENTAL",null,[13],"Diagnostic Test: DOTATATE-PET scan",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DIAGNOSTIC_TEST","DOTATATE tracer PET scan for meningioma",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Sandy Chang","CONTACT","6048776000","sandy.chang@bccancer.bc.ca",[26],{"facility":27,"status":11,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"BC Cancer - Vancouver","Vancouver","British Columbia","V5Z 4E6","Canada","CA",{"type":34,"coordinates":35},"Point",[36,37],-123.11934,49.24966,{"lat":37,"lon":36},[40,41],{"name":21,"role":22,"phone":11,"phoneExt":23,"email":24},{"name":42,"role":43,"phone":11,"phoneExt":11,"email":11},"Justin Oh, BA, MD, FRCPC","PRINCIPAL_INVESTIGATOR",{"type":45,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100588121","dotatate-pet-for-meningioma-radiation-planning-100588121",false,"NCT06937268","DOTATATE PET for Meningioma Radiation Planning","Exploratory Analysis of DOTATATE PET for Meningioma Radiation Planning","DOTATATE-RT","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Able and willing to comply with the study procedures\n* Intact meningioma requiring definitive radiation\n* Post-operative meningioma requiring adjuvant radiation\n* No prior radiation therapy or medical therapy directed at the tumour\n\nExclusion Criteria:\n\n* Breastfeeding or pregnancy\n* Claustrophobia or inability to lie still in a supine position\n* Unwillingness or inability to provide informed consent","ALL","18 Years",{"count":57,"type":58},36,"ESTIMATED","INTERVENTIONAL",[61],"NA","68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET",[64],"Meningioma","NOT_YET_RECRUITING","2025-04-15",{"date":68,"type":69},"2025-04-22","ACTUAL",{"date":71,"type":58},"2025-06",{"date":73,"type":58},"2027-12-31",{"name":5,"class":6},1]